ResMed's strong quarter spurs analyst upgrades, shares rise

The gist

ResMed surged past Wall Street’s expectations with a robust quarter, sparking analyst upgrades and a swift share price boost.

What to know

  • Q3 revenue jumped 6% to US$1.41 billion, with adjusted EPS up 14% and gross margin climbing to 62.5%.
  • Management kept FY27 guidance unchanged, signaling confidence for continued growth and helping shares rise about 2% to $36.15.
  • Analysts say the stock's 19–21x FY27 earnings multiple leaves room for upside—especially compared to Cochlear’s 27x valuation.

Guidance Fuels Analyst Optimism

ResMed’s strong Q3 beat and unwavering FY27 outlook convinced analysts to raise their forecasts, signaling deeper confidence in sustained growth beyond the headline numbers.

ResMed’s October print gave analysts a concrete reason to lift their models because the quarter came in ahead of the growth and margin profile investors had been braced for. Motley Fool Australia said the company “delivered a solid start to FY27,” with “a 6% increase in revenue to US$1.41 billion” and “adjusted gross margin improved by 50 basis points to 62.5%,” which “contributed to a 14% increase in adjusted earnings per share,” then added that “consensus EPS estimates could change for the better” after that encouraging start.

Just as important, the beat was not framed as a one-off: management maintained its FY27 guidance, expecting “reported revenue of US$5.75 billion to US$5.85 billion” and “core constant currency revenue growth of 5% to 7%,” with “adjusted earnings guidance” unchanged, reinforcing the case for higher valuation targets. That combination of earnings delivery and durable outlook fed directly into demand, with shares “up 2% to around $36.15 on Friday” after the release, while StockStory’s headline — “ResMed Beats Forecast with $1.41 B Revenue, Returns $1 B to Shareholders, Says CEO Mick Farrell” — underscored the confidence signal.

Sources
The Motley Fool AustraliaStockStory

Valuation Gap Signals Potential

ResMed trades at a notably lower earnings multiple than sector rival Cochlear, leaving room for share price gains as profitability and demand trends strengthen.

The case for a rerating worked because ResMed was not already priced like a no-mistakes growth stock. The Motley Fool Australia argued that at “$35.50,” ResMed shares were trading on a “PE ratio of approximately 21 times forecast FY27 earnings and 19 times FY28 estimates,” adding, “I think that's a reasonable valuation,” and, separately, “I would be happy buying ResMed shares before Friday's announcement… But I'm much more interested in where ResMed could be in five or ten years… And at around 19 times FY28 earnings,” the stock still looked buyable rather than fully priced.

That valuation also looked undemanding in relative terms, which helps explain why upgrades could still move the stock. The Motley Fool Australia noted that “At recent share prices, ResMed is trading on a price-to-earnings (PE) ratio of approximately 20 times consensus FY27 earnings according to CommSec,” while “Cochlear, meanwhile, trades at approximately 27 times earnings… I think the valuation gap is significant, especially given how the two businesses are performing,” a comparison made more telling because “ResMed's latest results showed strong demand for its products and improving profitability, with adjusted earnings per share increasing 14%.”

Sources
The Motley Fool AustraliaThe Motley Fool Australia

Get the stories behind the trends

Deep-dive reporting and the weekly brief, in your inbox.